Decompressive Craniectomy for Malignant Middle Cerebral Artery Stroke

Mark M. Landreneau, MD1  Kevin N. Sheth, MD2

1 Section of Neurocritical Care and Emergency Neurology, Yale University, New Haven, Connecticut
2 Department of Neurology, Yale University, New Haven, Connecticut
3 Department of Neurosurgery, Yale University, New Haven, Connecticut

Address for correspondence Kevin N. Sheth, MD, Department of Neurology, Yale University, PO Box 208018, New Haven, CT 06520 (e-mail: kevin.sheth@yale.edu).

Abstract

Keywords
- Decompressive Craniectomy
- decompressive hemispherectomy
- malignant
- ischemic stroke
- middle cerebral artery stroke
- hemispheric stroke
- malignant edema
- surgical decompression
- stroke edema

Advancements in the treatment of ischemic stroke have led to a recent decline in overall stroke mortality, but patients with hemispheric infarcts remain at high risk for death. Recent advances in the approach to this devastating disease include early identification of patients at high risk for swelling and standardized approaches to medical therapy. However, surgical decompression continues to be the most effective treatment for malignant edema from large hemispheric strokes. Patient selection in the past had been strictly limited to younger ages and the nondominant hemisphere. More recent evidence demonstrates a mortality benefit in older patients with a limited impact on morbidity. Judicious patient selection and shared, informed decision making with families remain the optimal approach for this devastating disease.

Large ischemic infarcts of the middle cerebral artery (MCA) territory carry significant risks of morbidity and mortality due to not only the destruction of a large volume of brain but also the progressive and deleterious effects of poststroke edema.1 Edema associated with large strokes follows a typical crescendo-decrescendo pattern over several days, in some cases leading to transtentorial herniation and progressive neurological decline, making them “malignant” (► Fig. 1). About 10% of supratentorial infarcts fall into this classification. In large prospective studies of these patients, mortality rates approach 60%2 for patients treated with medical therapy alone, though there likely exist some bias due to the self-fulfilling prophecy of early withdrawal of life sustaining therapies. Many surviving patients are left with profound neurological disability. Approximately two-thirds of survivors remain completely dependent on others (modified Rankin scale [mRS] 4–5).2

In light of these dispiriting facts, there remains some degree of controversy over the best approach to patients with malignant MCA stroke syndromes. The cumulative evidence over the past several years comparing standard of care medical therapy to surgical decompressive craniectomy has shown survival benefit and a trend to improved outcomes, and it remains the recommendation of the American Heart Association (AHA)/American Stroke Association (ASA)3 and Neurocritical Care Society,4 particularly for younger patients. As the current therapy exists, however, intervention often introduces a tradeoff between mortality and severe disability, which requires an individualized approach to care and patient values.
Predictors of Malignant Edema and Herniation

Clinical Features

In the anterior circulation, large hemispheric infarcts are most commonly embolic or thrombotic occlusions of the terminus of the internal carotid artery, “carotid T,” or of the proximal segment of the MCA, radiographically designated as M1.\(^1\) The clinical syndrome is typically sudden onset of profound deficits—hemiplegia, gaze deviation, homonymous quadrantanopsia or hemianopsia, and either aphasia or neglect, depending on hemisphere. As the infarcted tissue swells, the syndrome can progress to decreased levels of consciousness because of elevated intracranial pressure (ICP) or distortion of bilateral projections from the reticular activating system.\(^5\) Of note, a large randomized prospective study has shown the early appearance of decreased arousal is a poor prognostic sign.\(^6\) Delayed focal findings such as pupillary dilatation, cranial nerve palsies, and ipsilateral hemiparesis can appear due to herniation of the temporal lobe against the midbrain.

In large retrospective case series, there have been several clinical features identified as independent predictors of developing a malignant MCA syndrome. A major epidemiological risk factor is younger age,\(^7,8\) which is in part due to a combination of larger brain volume compared with older patients with decreased intracranial space for swelling.\(^1,7\) A postmortem analysis\(^9\) also found specific features of patients who died of malignant infarcts including no history of stroke, female sex, elevated heart weight, abnormal ipsilateral circle of Willis, and carotid occlusion. Other independent risk factors shown to be predictors of malignant infarction include a history of hypertension, which may lead to a poor autoregulation and impaired collateral perfusion\(^10,11\); systolic blood pressure >180 mm Hg after 12 hours from onset\(^7\); and a history of heart failure as well as elevated peripheral white blood cell count.\(^10\)

Radiographic Features

Computed Tomography

Advanced imaging such as diffusion magnetic resonance imaging (MRI), perfusion computed tomography (CT), and MRI are becoming more widely used in the assessment of acute stroke, but noncontrast head CT remains the most widely used neuroimaging study in acute stroke. Two large retrospective case-control studies\(^7,10\) demonstrated that involvement of more than 50% of the MCA territory on head CT at 2 to 3 hours poststroke onset was an independent predictor of fatal brain edema. When studied prospectively,\(^12\) more than 80% of patients with >50% infarction on CT within first 3 hours developed a fatal malignant MCA syndrome. In the same study, additional findings with high positive predictive value (PPV) for death from malignant edema included local brain swelling (70% PPV) and a hyperdense MCA trunk (32% PPV). Quantified, an infarct volume >220 mL and midline shift >3.9 mm are predictive of severe brain edema leading to herniation.\(^13\) Alberta Stroke Program Early CT Score (ASPECTS) can be used as a more formal grading system, and scores <7 are associated with progression to malignant infarction (50% sensitivity and 85% specificity).\(^14\)

Computed Tomography Perfusion and Flow Studies

The major limitation of noncontrast head CT is poor sensitivity, particularly early in the clinical course of stroke, a limitation that can be improved with the addition of contrast-based perfusion studies to identify large core infarcts. An infarct core volume greater than two-thirds of the MCA territory on CT perfusion predicted malignant edema with high sensitivity (92%) and high specificity (94%).\(^15\) When additional large vessel territories are involved as core infarct, particularly with carotid occlusions, the likelihood of malignant infarct is even higher.\(^16\) Furthermore, in large strokes (National Institutes of Health Stroke Scale [NIHSS] >18), poor

---

**Fig. 1 Noncontrast head CT of a patient with a malignant right middle cerebral artery infarct (A) before and (B) after decompressive hemicraniectomy. Preoperative CT shows large territory of hypodensity. Postoperative scan demonstrates edema, hemorrhagic transformation, and mass effect. CT, computed tomography.**
collateral circulation scores were independently associated with malignant infarction.\textsuperscript{17}

Xenon CT scanning can also been used for early identification of malignant stroke syndromes. In a retrospective study of 20 patients,\textsuperscript{18} a xenon CT scan within 6 hours of symptom onset that demonstrated hemispheric cerebral blood flow $\leq 15 \text{ mL}/100 \text{ g per minute}$ was associated with severe edema and herniation (sensitivity 100% and specificity 50%).

**Magnetic Resonance Imaging**
Compared with noncontrast head CT, MRI of the brain better predicts malignant edema in the earliest stages of infarction. In particular, diffusion-weighted imaging (DWI) has shown to have high sensitivity and specificity for predicting malignant edema. In one series of 28 patients,\textsuperscript{19} DWI infarct volumes $> 145 \text{ mL}$ within 14 hours of symptom onset were predictive of malignant infarction (100% sensitivity and 94% specificity). A larger prospective study of 140 patients\textsuperscript{20} showed that DWI volumes within 6 hours of symptom onset $> 82 \text{ mL}$ predicted malignant infarction with high specificity (98%) but low sensitivity (52%). A retrospective analysis\textsuperscript{21} showed that using MRI to measure the degree of brain atrophy can further increase PPV of lower volume DWI lesions ($> 87 \text{ mL}$) for the development of malignant edema (0.93 vs. 0.70).

**Tissue Metabolism Imaging**
Small studies of single photon emission CT (SPECT) and 11C flumazenil positron emission tomography (PET) have shown they can be used to assess volumes of infarct core and predict malignant course with a high sensitivity. When performed in the first 24 hours of symptom onset, the sensitivity of SPECT in predicting herniation due to brain edema has been shown to have higher sensitivity than noncontrast head CT (82 vs. 36%) with similar specificity.\textsuperscript{22}

Likewise, in a study of 34 patients with early CT changes showing ischemic changes in $> 50\%$ territory of MCA territory, flumazenil PET was shown to be useful to predict malignant course.\textsuperscript{23} Patients with malignant courses had a larger mean ischemic core than those with benign courses, 144.5 versus 62.2 mL.

**Biomarkers and Serum Markers**
Though biomarkers have some utility as corroborative data in conjunction with imaging and clinical data, they have not shown readily available utility as independent predictors. Invasive monitoring with microdialysis of cerebral spinal fluid in the area of the stroke bed has demonstrated elevations in excitatory neurotransmitters such as glutamate and aspartate in addition to an anaerobic metabolic profile with in lactate and lactate/pyruvate ratios in patients who went on the develop malignant syndromes.\textsuperscript{23}

There are a few serum markers that have been studied as potentially useful for predicting malignant course. A serum protein marker of glial injury, SB100, has been shown to rise in proportion with size of infarct.\textsuperscript{24} Significant elevations in the first 12 to 24 hours poststroke have been associated with an increased risk of herniation in patients with large MCA strokes.\textsuperscript{25} Another small case–control study showed serum cellular fibronectin could predict a malignant course when present in very elevated levels ($> 16.6 \mu \text{g/mL}$).\textsuperscript{26} There is also some evidence that high matrix metalloproteinase 9 levels are associated with increased vasogenic edema and risk of malignant infarct.\textsuperscript{27}

**Predictive Models**
Multiple clinical grading scales have been developed to better predict risk of a developing a malignant MCA syndrome. The EDEMA\textsuperscript{28} score is a proposed score that uses basal cistern effacement (yes: 3; no: 0), serum glucose ($\geq 150$: 2; $< 150$: 0), midline shift ($> 9 \text{ mm}$: 7; 6–9 mm: 4; 3–6 mm: 2; 0–3 mm: 1; 0 mm: 0), previous stroke (no: 1; yes: 0), and tissue plasminogen activator or thrombectomy (no: 1; yes: 0) as predictive variables for malignant edema. It has not yet been validated, but a score $> 7$ confers a 93% PPV for development of malignant edema.

The DASH\textsuperscript{29} score is another predictive model that uses four variables: DWI ASPECTS ($\leq 3$: 1 point; $> 3$: 0 point), anterior cerebral artery territory involvement (yes: 1 point; no: 0 point), M1 susceptibility vessel sign (yes: 1 point; no: 0 point), and hyperglycemia ($\geq 145$: 1 point; $< 145$: 0 point). The likelihood of developing a malignant infarction was scaled according to score. A score of 0 was 9.1%; score 1: 20.5%; score 2: 63.0%; and scores 3 and 4: 96.8%.

Another score\textsuperscript{30} has used NIHSS ($\geq 18$: 2 points; 9–17: 1 point; $\leq 9$: 0 point) ASPECTS ($\leq 7$: 1 point; $> 8$: 0 point), collateral score ($< 2$: 2 points; $\geq 2$: 0 point), and revascularization failure (yes: 1 point; no: 0 point). More than 80% of patients with a score of 5 and all patients with a score of 6 developed malignant brain edema.

**Treatment**

**Decompressive Craniectomy**
Traditional medical management of malignant MCA stroke involves the use of hyperosmolar therapy, sedation, and hyperventilation. The evidence for significant mortality and morbidity benefit from these conservative therapies remains unclear.\textsuperscript{31–34} Intravenous glyburide has shown some evidence of reducing stroke-associated edema\textsuperscript{35} but remains in early stages of investigation.

Because of the current limitations of medical therapy in controlling malignant edema, decompressive craniectomy provides an adjunctive measure to allow for brain expansion outside the cranial vault. The surgery involves incising and reflecting a large portion of the scalp to expose the frontal, parietal, and temporal bones. A large bone flap with wide margins around the stroke bed is then removed. Current recommendations are for a bone flap of at least 12 cm,$^4$ and possibly up to 13 to 14 cm for some patients.\textsuperscript{36} The bone flap is then stored in a refrigerated tissue bank or intraperitoneally. A cruciate incised durotomy is performed to allow for swelling out of the cranial vault, and in some cases, necrotic tissue may be removed, although this is typically avoided to preserve intermixed areas of healthy tissue within the stroke bed. The goal of therapy is to reduce ICP, improve regional
perfusion, decrease midline shift, and prevent fatal compression of the brain stem due to edematous brain.

One of the first reports of using decompressive craniectomy for stroke was a case series in 1956. Once CT and advanced imaging became more widespread, early detection of stroke led to more frequent consideration of decompression. Several case series demonstrated a trend toward survival benefit with decompressive craniectomy, which prompted investigation with multiple prospective randomized controlled trials. Overall, these trials have demonstrated a mortality benefit with early decompression in addition to aggressive medical care, but survivors are often left with moderate-to-severe disability. Questions of the net benefit of decompression remain in light of this mortality disability trade-off, but careful patient selection can provide a subset of patients not just with a significant mortality but also morbidity benefit.

**Outcomes Data**

Two large meta-analyses have been performed on currently available clinical trial data. The first review in 2015 evaluated six high-quality trials from 2007 to 2014: DECIMAL, DESTINY, HAMLET, DESTINY II, HeADDFIRST, and another large prospective trial. A total of 317 patients were included in the analysis. Criteria for inclusion were patients with a malignant MCA stroke who were randomized to medical therapy alone or medical therapy and surgical decompression. Follow-up was performed at 6 and 12 months using the mRS. Several conclusions were drawn from the following pooled analysis:

1. There is a significant survival benefit to surgical decompression. The odds ratio for death (mRS 6) in the decompressive surgery group compared with standard medical management group was statistically significant at 0.17 (95% CI: 0.10–0.29).
2. The frequency of patients with severe disability in the surgical decompression group was higher compared with medical therapy. The number of patients with a mRS of 3 or 5 was higher in the decompressive surgery group but did not reach statistical significance. The number of patients with a mRS of 4 was statistically significant; odds ratio [OR] of 4.43 (95% CI: 2.27–8.66).
3. Some patients had a significant morbidity benefit. The number of patients with mRS of 2 was significantly higher in the surgical decompression group with an OR of 4.51 (95% CI: 1.06–19.24).
4. Previous reviews suggested benefit only up to the age of 60 years for surgical decompression, but the researchers here found mortality benefit extends up to the age of 80 years. Three trials in the dataset included a large number of older patients: DESTINY II included only patients of 61 to 80 years old, Frank et al. included patients up to the age of 75 years, and Zhao et al. included patients up to the age of 80 years.

Another large meta-analysis in 2016 had many similar conclusions to the one the year prior. A total of 338 patients were included from seven trials: DECIMAL, DESTINY, HAMLET, DESTINY II, HeADDFIRST, Zhao et al., and Slezins et al. They made the following observations based on 12-month follow-up data:

1. There was a significant reduction in mortality in the surgical decompression group compared with best medical management. The craniectomy group had 39% fewer deaths. The chance of being a survivor in the surgical group had a relative risk (RR) of 2.05 (95% CI: 1.54–2.72). The quality of evidence for this finding was high.
2. Severe disability was higher in the surgical decompression group. There were 4% more patients in the mRS 5 group and 22% more in mRS 4. The quality of evidence for this finding was moderate.
3. Mild-to-moderate disability was also increased in the surgical group. The chances of surviving with a mRS of 3 or less by RR of 1.58 (95% CI: 1.02–2.46). However, the quality of evidence for this finding was low.
4. The impact of age older than 60 years was not significant with respect to mortality risk.
5. Timing of surgery within 48 or 96 hours did not have a significant impact on outcome.

**Further Considerations**

Given the evidence that shows a significant mortality benefit to decompressive craniectomy as well as a significant trend toward reduced morbidity, the remaining considerations include age, decompression of dominant versus nondominant hemisphere stroke, timing of surgery, procedural complications, cost, and most importantly considerations of patient values.

**Age**

The DESTINY II trial provided the first and only dedicated randomized controlled data for surgical decompression versus maximal medical therapy in older patients with malignant MCA infarct. The study showed that for patients, age 60 to 80 years, there was a significant mortality benefit of surgical decompression. At 1 year, mortality was 76% in the medical control arm versus 43% in the surgical decompression arm.

However, 51% of patients in the surgical arm had a mRS ≥ 4 compared with 19% in the medical arm. Only 5% of patients in the surgical arm had a mRS of 3, there were none with a mRS of < 3. This number is substantially lower compared with the combined results of previous randomized trials in all patients, where > 25% of patients in the surgical arm had a mRS of < 3. These results show there is a significant risk that decompressive craniectomy will be a lifesaving but debilitating procedure, and though it is not an exclusionary criteria, the strong need for informed decision making with older patients and their decision makers is clear.

**Dominant versus Nondominant Hemisphere**

Because of the high risk of residual severe aphasia in patients with dominant hemisphere malignant syndromes, offering lifesaving craniectomy remains a somewhat controversial choice. Functional outcome scores such as the mRS do not adequately capture differences between hemiplegic patients with respect to language as both will score 4 or 5. However,
this consideration should be tempered by the recognition that nondominant hemisphere strokes can be profoundly disabling apart from motor function due to neglect syndromes as well as more subtle cognitive, emotional, and behavioral changes. Furthermore, there is limited data showing significant improvement in aphasia postcraniectomy for malignant stroke. One study followed a group of 14 patients, and in 13, a significant language improvement was seen at 1 year.\(^{49}\) Furthermore, patients' preferences may not be as straightforward as expected, and as one study\(^ {50}\) has shown that global aphasia may be considered better than hemiplegia, which was for many to be considered worse than death. Though the likelihood of significant disability with or without aphasia should be communicated to decision makers, no strict exclusionary principle should be applied to patients with dominant hemisphere stroke in light of these complicated and individual factors.

**Timing of Surgery**

As a theoretical point, it stands that early surgery, prior to the signs of herniation, would offer best clinical outcomes for decompressive craniectomy. Avoiding significant elevations in ICP and clinically apparent signs of herniation would seem to offer the best chance at preserving maximal brain tissue. Multiple animal models\(^ {51,52}\) have suggested as much, but clinical evidence for significant benefit from early surgery has not been as robust.

Nonrandomized data on patient outcomes has not had any definitive suggestion of benefit for early treatment. A 2004 review of nonrandomized studies of patients treated with craniectomy\(^ {18}\) did not show a significant difference in outcomes based on time to treatment. Another retrospective study of 1,301 patients who had decompressive craniectomy for stroke showed a mild increased risk of disability, in particular, discharge to a facility associated with surgery after 48 hours (OR: 1.17, 95% CI: 1.05–1.31), but these data were not controlled for confounders such as age.\(^ {53}\)

The data from randomized controlled trials are, in short, insufficient to draw a conclusion regarding the benefits of earlier surgery. Based on enrollment patterns of the large randomized controlled trials for decompression, patients can be grouped into very early surgery (<24 hours postsymptom onset), early surgery (24–48 hours), and delayed (48–96 hours). A pooled analysis of three early randomized controlled trials\(^ {47}\) showed no difference between very early or early surgery with respect to mortality or functional outcome. In the HAMLET\(^ {54}\) and HeADDFIRST\(^ {45}\) trials, some patients enrolled in the surgical arm received decompressive craniectomy up to 96 hours postsymptom onset. In HAMLET trial, 11 patients received surgery after 48 hours, and HeADDFIRST trial had only 8 patients with late decompression. Compared with early surgery, there was no statistically significant difference in mortality, and the numbers were too small to draw any definitive conclusions about benefits.
though there was a trend toward a benefit in functional outcome with early surgery. As there was no randomization regarding timing of treatment, patient selection bias cannot be excluded and until a dedicated randomized controlled trial examining early versus late surgery is performed, there is no evidence-based strict exclusion to delayed surgery.

Procedural and Postprocedural Complications
There are several acute and chronic complications of decompressive craniectomy. Acute complications include hydrocephalus, infection, seizures, and external brain tamponade. Chronic complications include sinking skin flap syndrome and paradoxical herniation. A study of the DECIMAL trial showed ~10% of patients developed symptomatic sinking skin flap syndrome, and another 15% had asymptomatic radiographic evidence of SSFS.

Sinking skin flap syndrome is a common chronic complication of craniectomy due to atmospheric pressure causing large brain tissue shifts due to low ICP. The area beneath a skull defect will appear depressed and shifted toward the contralateral side. If left untreated, it can become symptomatic, causing a low pressure headache or focal weakness, and in the most extreme cases, it can progress to paradoxical brain herniation, coma, and death. Definitive treatment is cranio-plasty and bridging therapies include clamping cerebrospinal fluid draining, Trendelenburg position, volume resuscitation, avoidance of hyperosmolar therapy and hyperventilation, and head positioning with skin flap site down.

Patient Values and Quality of Life
Only two of the major randomized controlled trials for decompressive craniectomy used quality-of-life measurements in their outcomes assessment. In HAMLET trial, quality of life was measured by Medical Outcome Study (SF-86) and a visual analog scale. They did not find any significant differences between the medical and surgical groups except for the physical summary score, which was better in the medical arm.

The DECIMAL trial also evaluated quality-of-life outcomes via the French version of the stroke impact scale, an eight-domain scale with four psychosocial and four physical domains. There were no significant differences in quality of life between the groups, and the authors noted that all survivors were able to acknowledge “life is worth living.”

Further reports rely on limited data from trials and observational studies. One study found a majority of patients who survive would have chosen the same course if they had the option again. Another found that among 64 survivors of craniectomy who had undergone rehabilitation and recovery, 69% of patients and families would consider decompressive craniectomy again if they had to make the choice again. With that said, the HAMLET study found that more than 70% of caregivers experienced high levels of stress in their daily lives in 3 years after stroke.

Cost
High rates of disability among survivors of craniectomy have introduced concerns not only the quality of life of survivors but also the costs. Investigators of the HAMLET study performed a cost-effectiveness analysis of surgical decompression for the first 3 years comparing patients treated in the surgical decompression arm versus the medical treatment arm. They found that compared with medical therapy, surgical craniectomy increases quality-adjusted life years (QALYs) at a mean difference of 1.0 QALY (95% CI: 0.6–1.4) but a high cost, a mean difference of €127,000 (95% CI: 73,100–181,000) per QALY gained in the first 3 years. Estimated over a lifetime, they predicted approximately €60,000 per QALY gained.

Recommendations
A Statement for Healthcare Professionals from the Neurocritical Care Society and the German Society of Neuro-Intensive Care and Emergency Medicine has the following evidence-based recommendations:

1. Decompressive craniectomy after hemispheric infarct (strong recommendations, high quality of evidence)
2. For patients >60 years of age, a greater reliance on patient and family input (strong recommendation, moderate quality of evidence)
3. Early decompression (24–48 hours after onset) prior to herniation symptoms (strong recommendation, moderate quality of evidence).

These recommendations are in line with previous guidelines of the AHA/ASA but updated with evidence on older patients from the interim DESTINY II trial. In light of the available evidence and therapeutic options, we recommend that for patients younger than 60 years with an infarct of at least 50% of the MCA territory and high risk for progression to a malignant syndrome, aggressive medical management with early decompressive craniectomy (<48 hours) prior to the onset of signs of brain stem injury. Decompression may also be considered for patients within a 96-hour window. For patients who are older than 60 years, surgical decompression may remain an option but pursued after thorough discussion with primary decision makers regarding patient values given the high rates of severe disability in survivors.

References

\* At current exchange rates £1 = $1.18. €127,000 ≥ $150,000.
Decompressive Cranietomy for Malignant MCA Stroke  
Landreneau, Sheth 743


Akins PT, Guppy KH. Sinking skin flaps, paradoxical herniation, and external brain tamponade: a review of decompressive craniectomy management. Neurocrit Care 2008;9(02):269–276


